Streetbeat News

ATHX

Athersys Inc

http://www.athersys.com/

CEO

Gil Van Bokkelen

Employees

Industry

Pharmaceutical Preparation Manufacturing

athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. we are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. this pipeline includes both stem cell therapy and pharmaceuticals.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Athersys reported a third-quarter earnings per share (EPS) of $(0.15), indicating a loss for the quarter.

Portfolio Pulse from Benzinga Newsdesk

November 16, 2023 | 1:36 pm

During Tuesday's after-market session, several health care stocks experienced significant movement. Biocept (BIOC), Intelligent Bio Solutions (INBS), RVL Pharmaceuticals (RVLP), Virpax Pharmaceuticals (VRPX), Exagen (XGN), and PaxMedica (PXMD) saw their shares rise, while Athersys (ATHX), Eiger BioPharmaceuticals (EIGR), China SXT Pharmaceuticals (SXTC), Ultragenyx Pharmaceutical (RARE), Bio-Rad Laboratories (BIO), and Inspire Veterinary (IVP) experienced a decline in their stock prices.

Portfolio Pulse from Benzinga Insights

October 17, 2023 | 9:31 pm

The article lists the stocks that gained and lost in Tuesday's mid-day session. Notable gainers include SciSparc Ltd., Assembly Biosciences, Inc., and Olink Holding AB, while notable losers include Evelo Biosciences, Inc., Monte Rosa Therapeutics, Inc., and Nuvve Holding Corp. The article also mentions that ServisFirst Bancshares shares are trading lower by 6% after the company reported third-quarter earnings.

Portfolio Pulse from Lisa Levin

October 17, 2023 | 5:42 pm

During Tuesday's pre-market session, several health care stocks experienced significant movement. Assembly Biosciences (ASMB), Olink Holding (OLK), Athersys (ATHX), Monte Rosa Therapeutics (GLUE), Akso Health Group (AHG), and Vigil Neuroscience (VIGL) saw their shares increase, while Evelo Biosciences (EVLO), Purple Biotech (PPBT), Redhill Biopharma (RDHL), Kodiak Sciences (KOD), Processa Pharma (PCSA), and XTL Biopharmaceuticals (XTLB) experienced a decrease in their share prices.

Portfolio Pulse from Benzinga Insights

October 17, 2023 | 1:06 pm

Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) rose by 12.6% in pre-market trading after Citadel Advisors LLC reported a 5.6% stake in the company. Other notable gainers include SciSparc Ltd. (NASDAQ:SPRC), WiSA Technologies, Inc. (NASDAQ:WISA), and Athersys, Inc. (NASDAQ:ATHX). On the other hand, Nuvve Holding Corp. (NASDAQ:NVVE), NetScout Systems, Inc. (NASDAQ:NTCT), and Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) were among the losers.

Portfolio Pulse from Lisa Levin

October 17, 2023 | 12:12 pm

Athersys has initiated a warrant exercise inducement offer to raise up to $3.9M from the exercise of 28,124,590 warrants. The company has also received the first tranche payment of $1.5M from Healios K.K. under the ARDS global license.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 8:55 pm

Athersys, Inc. (NASDAQ:ATHX) has raised up to $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. under the acute respiratory distress syndrome (ARDS) global license. The company has also engaged Outcome Capital to assist with evaluating strategic alternatives, including a possible merger, business combination, investment into the company, or a purchase, license, or other acquisition of assets. If Athersys is unable to enter into a strategic transaction or obtain adequate financing, it may have to file for bankruptcy.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 8:54 pm

In Wednesday's pre-market session, several healthcare stocks saw significant movement. Tempest Therapeutics, SINTX Techs, Celularity, Athersys, Phio Pharma, and Trinity Biotech experienced gains, while Silk Road Medical, DaVita, Fresenius Medical Care, Outset Medical, Kazia Therapeutics, and Sunshine Biopharma saw decreases.

Portfolio Pulse from Benzinga Insights

October 11, 2023 | 1:06 pm

Several stocks are experiencing significant pre-market trading movements. Tempest Therapeutics (TPST) shares rose 279.8% following an announcement of new data from a global study. Wheeler Real Estate Investment Trust (WHLR) shares gained 211% after a 7% fall on Tuesday. Athersys (ATHX) shares rose 20.7% as the company plans to conduct additional data analysis. Gaucho Group Holdings (VINO) shares climbed 42.7% after announcing its move towards organic cultivation. VOXX International Corp (VOXX) shares rose 11.7% as the company reported stronger-than-expected sales for Q2.

Portfolio Pulse from Lisa Levin

October 11, 2023 | 12:24 pm

In Tuesday's after-market session, several health care stocks saw significant movement. Tempest Therapeutics (TPST), Athersys (ATHX), Cardio Diagnostics Hldgs (CDIO), Yield10 Bioscience (YTEN), Processa Pharma (PCSA), and Moleculin Biotech (MBRX) all saw increases, with Tempest Therapeutics leading the gainers with a 325% increase. On the other hand, Silk Road Medical (SILK), DaVita (DVA), Fresenius Medical Care (FMS), Baxter Intl (BAX), PaxMedica (PXMD), and Outset Medical (OM) all saw decreases, with Silk Road Medical leading the losers with a 33.9% decrease.

Portfolio Pulse from Benzinga Insights

October 10, 2023 | 9:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.